Vancouver, British Columbia–(Newsfile Corp. – August 14, 2019) – XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (“XPhyto” or the “Company”) is pleased to announce that its wholly owned German subsidiary, Bunker Pflanzenextrakte GmbH (“Bunker”), has entered into an exclusive cannabis research and development agreement (the “RD Agreement”) with the department of biochemistry at the Technical University of Munich (“TUM”).
Pursuant to the RD Agreement, initial research will focus on the identification and assessment of novel research and development approaches to utilize the cannabis plant and its derivatives, including cannabinoids, terpenes, terpenoids, polyphenols and flavones. Promising targets will be advanced through pilot studies and pending preliminary success, pursued via separate joint research projects on a case-by-case basis for potential commercialization.
“XPhyto is honored to have the privilege of working with TUM. Their commitment to research